145 related articles for article (PubMed ID: 12460403)
1. Mobilization factors of peripheral blood stem cells in healthy donors.
Shimizu N; Asai T; Hashimoto S; Narita M; Kobayashi M; Ito M; Onoda M; Yokota A; Cho R; Nakaseko C; Nishimura M; Saito Y
Ther Apher; 2002 Dec; 6(6):413-8. PubMed ID: 12460403
[TBL] [Abstract][Full Text] [Related]
2. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
3. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
[TBL] [Abstract][Full Text] [Related]
4. Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells.
Hashimoto S; Itoh M; Nishimura M; Asai T
Ther Apher; 2002 Dec; 6(6):431-6. PubMed ID: 12460406
[TBL] [Abstract][Full Text] [Related]
5. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
Engelhardt M; Bertz H; Wäsch R; Finke J
Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
7. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study.
Bertani G; Santoleri L; Martino M; Fedele R; Moscato T; Marenco P; Grillo G; Zucchetti E; Lotesoriere I; Lando G; Cesana C; Cairoli R; Rossini S
Transfusion; 2014 Aug; 54(8):2028-33. PubMed ID: 24588265
[TBL] [Abstract][Full Text] [Related]
8. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.
Stroncek DF; Clay ME; Petzoldt ML; Smith J; Jaszcz W; Oldham FB; McCullough J
Transfusion; 1996 Jul; 36(7):601-10. PubMed ID: 8701455
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?
Lysák D; Kořístek Z; Gašová Z; Skoumalová I; Jindra P
J Clin Apher; 2011; 26(1):9-16. PubMed ID: 21312254
[TBL] [Abstract][Full Text] [Related]
11. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.
Hsu JW; Wingard JR; Logan BR; Chitphakdithai P; Akpek G; Anderlini P; Artz AS; Bredeson C; Goldstein S; Hale G; Hematti P; Joshi S; Kamble RT; Lazarus HM; O'Donnell PV; Pulsipher MA; Savani BN; Schears RM; Shaw BE; Confer DL
Biol Blood Marrow Transplant; 2015 Jan; 21(1):165-71. PubMed ID: 25316111
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience.
Anderlini P; Donato M; Chan KW; Huh YO; Gee AP; Lauppe MJ; Champlin RE; Körbling M
Transfusion; 1999 Jun; 39(6):555-60. PubMed ID: 10378833
[TBL] [Abstract][Full Text] [Related]
13. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used.
Ings SJ; Balsa C; Leverett D; Mackinnon S; Linch DC; Watts MJ
Br J Haematol; 2006 Sep; 134(5):517-25. PubMed ID: 17018030
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age.
Martino M; Bonizzoni E; Moscato T; Recchia AG; Fedele R; Gallo GA; Console G; Messina G; Morabito F
Biol Blood Marrow Transplant; 2015 May; 21(5):881-8. PubMed ID: 25636377
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.
Hölig K; Kramer M; Kroschinsky F; Bornhäuser M; Mengling T; Schmidt AH; Rutt C; Ehninger G
Blood; 2009 Oct; 114(18):3757-63. PubMed ID: 19666868
[TBL] [Abstract][Full Text] [Related]
17. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P
Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131
[TBL] [Abstract][Full Text] [Related]
18. The effect of age on peripheral stem cell mobilization in healthy donors, single center experience.
Ozen M; Gunduz M; Topcuoglu P; Toprak SK; Dalva K; Gurman G; Ilhan O
J Clin Apher; 2017 Feb; 32(1):16-20. PubMed ID: 26958783
[TBL] [Abstract][Full Text] [Related]
19. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
20. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.
Hsu JW; Shaw BE; Kim S; Logan BR; Sees JA; Confer DL; Pulsipher MA; Shah N; Switzer GE; Abidi MH; Ahmed IA; Anderlini PN; Bredeson C; Chhabra S; Dandoy CE; Diaz MA; Farhadfar N; Ganguly S; Gergis U; Hale GA; Hematti P; Kamble RT; Kasow KA; Lazarus HM; Liesveld JL; Murthy HS; Olsson RF; Savani BN; Schears R; Seo S; Solh M; Spitzer T; Steinberg A; Sugrue M; Warkentin P; Wingard JR
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1210-1217. PubMed ID: 32088366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
